NDAORALTABLET
Approved
Oct 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
6/8 — Strong
COMTAN (entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 1999.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMTAN (entacapone) is an oral small-molecule catechol-O-methyltransferase (COMT) inhibitor approved in 1999 for Parkinson's disease and methamphetamine dependence. It works by inhibiting COMT, an enzyme that breaks down dopamine, thereby extending the duration of action of levodopa in Parkinson's patients. The drug is taken as a tablet and is used as an adjunctive therapy to enhance dopaminergic activity in the central nervous system.
$33,000Part D
LOE ApproachingMinimal commercial activity with only $33K in Part D spending and 23 claims in 2023, suggesting a mature, niche product with a small and likely consolidating brand team.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
Started Jan 2026
215 enrolled
Advanced Parkinson Disease
Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease: An Observational, Multicenter, Case-Control Study
Started Jun 2025
216 enrolled
Parkinson Disease (PD)
Pilot Study of Entacapone for Methamphetamine Abuse
Started Jun 2014
29 enrolled
Methamphetamine Dependence
Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens
Started Feb 2011
27 enrolled
Parkinson's Disease
Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off
Started Aug 2008
0Parkinson's Disease
Worked on COMTAN at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.